Vir Biotechnology (NASDAQ:VIR) Bolsa

VIR BIOTECHNOLOGY INC

Vir Biotechnology

Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

Vir Biotechnology Inc

Viratech Corp

Neuralbase AI Ltd

Virco Manufacturing Corporation - Common Stock

Virco Manufacturing Corp

Viridien

Pacer Funds Trust BioThreat Strategy ETF

Virtu Financial, Inc. - Class A Common Stock

Virtu Financial Inc

VIRACTA THERAPEUTICS INC by Viracta Therapeutics, Inc.

Viracta Therapeutics Inc

WIIM

Dynatrace shares are trading higher following better-than-expected Q4 earnings and strong guidance.

AMGN

GILD

Shares of pharmaceutical stocks are trading lower. The sector may down on continued weakness amid President Trump's drug pricing executive order.

The U.S. Centers for Medicare &amp; Medicaid Services (CMS) on Monday issued a draft guidance for public comment on the third cycle of negotiations under the Medicare Drug Price Negotiation Program (Negotiation Program) to <a target="_blank" href="https://www.benzinga.com/25/05/45234032/fda-expands-surprise-inspections-at-foreign-drug-and-food-facilities-targets-double-standards-in-overseas-manufacturing-oversight" rel="noreferrer noopener">lower prescription drug prices</a>.
The draft guidance introduces new policies that would, for the first time, include drugs covered under Medicare Part B in the Medicare <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">Drug Price Negotiation Program</a>.
The <a target="_blank" href="https://www.cms.gov/newsroom/press-releases/cms-releases-draft-guidance-third-cycle-medicare-drug-price-negotiation-program-lower-drug-prices" rel="noreferrer noopener">guidance</a> also explains how CMS plans to renegotiate prices for some drugs already negotiated for 2026 or 2027.
It clarifies how drugmakers must make the negotiated prices available in those years and extends similar rules for Part D drugs through 2028.
The first round of negotiations, covering 10 Part D drugs, ended in August 2024. A second round, <a target="_blank" href="https://www.benzinga.com/25/01/43062779/popular-ozempic-wegovy-selected-for-next-round-of-medicare-drug-price-negotiations" rel="noreferrer noopener">involving 15 more Part D drugs</a>, is currently underway.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45341590/trumps-drug-pricing-executive-order-could-rattle-pharma-stocksprice-cuts-up-to-80" rel="noreferrer noopener">Trump&#8217;s New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&amp;J Fall In Premarket</a>
By Feb. 1, 2026, CMS will announce up to 15 additional drugs, covered under either Part D or Part B, for possible negotiation in the third round. Negotiations for this third group will happen in 2026, with new prices taking effect Jan. 1, 2028.
On the same date, CMS will publish the list of drugs selected for initial price negotiations for 2028 and announce any drugs picked for a first round of renegotiation. Those updated prices will also start on January 1, 2028.
CMS invites the public to comment on this draft guidance, including the drug selection process, how negotiated prices are implemented, and ways to improve the program.
The public comment period is open for 45 days. Comments must be submitted by June 26.
Goldman Sachs analyst Asad Haider says investors are concerned about fixed-combination drugs. The draft points out cases where one ingredient affects how the drug is absorbed but doesn&#8217;t treat the disease itself. This has led to worries that some subcutaneous (SC) versions of drugs that IV originally gave might be included in Medicare price negotiations under the Inflation Reduction Act (IRA) earlier than expected.
The prior CMS guidance issued under the Biden Administration suggested that sub-q formulations of IV drugs could be excluded from IRA price negotiations.
Stocks of companies with key SC drugs in focus, Johnson &amp; Johnson&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) Darzalex Faspro, Bristol-Myers Squibb &amp; Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Opdivo Qvantig, and Merck &amp; Co Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) subcutaneous pembrolizumab/Keytruda (in development), are trading lower.
&#8220;At a higher level, we view this development as another aspect of policy uncertainty that continues to persist, in addition to the Most Favored Nation Executive Order and potential for tariffs&#8230;In our view, this underscores a need for the industry to pursue novel innovations over incremental life cycle management strategies — a dynamic which we believe could lead to increased M&amp;A activity,&#8221; analyst Haider writes.
Price Action: JNJ stock is down 1.45% at $146.30, BMY stock is down 2.64% at $45.38, and MRK stock is down 2.46% at $74.74&nbsp;at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/large-cap/25/05/45409509/samsungs-1-7-billion-cooling-spree-buys-flaktgroup-to-target-data-center-boom" target="_blank" rel="noreferrer noopener">Samsung&#8217;s $1.7 Billion Cooling Spree &#8211; Buys FläktGroup To Target Data Center Boom</a></li>
</ul>
Image: Shutterstock

Analyst Color

Biotech

Government

Large Cap

News

Regulations

Health Care

Analyst Ratings

Movers

Trading Ideas

General

CMS Expands Medicare Drug Price Talks To Part B Meds In 2026 Shake Up

The U.S. Food and Drug Administration (FDA) granted accelerated approval to AbbVie&nbsp;Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) Emrelis&nbsp;(telisotuzumab vedotin-tllv) for adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression (OE) who have <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">received a prior systemic therapy</a>.
High c-Met protein overexpression is defined as ≥ 50% of tumor cells with strong (3+) staining as determined <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45415840/u-s-fda-approves-emrelis-telisotuzumab-vedotin-tllv-for-adults-with-previously-treated-advanced-no" rel="noreferrer noopener">by an FDA-approved test</a>.
This indication is approved based on overall response rate (ORR) and duration of response (DOR).
Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s), the company said in a statement on Wednesday.
Also Read: <a target="_blank" href="https://www.benzinga.com//node/45079377" rel="noreferrer noopener">AbbVie Scores FDA Approval For Its Blockbuster Drug Rinvoq To Treat Type Of Arthritis</a>
Emrelis is a c-Met-directed antibody-drug conjugate (ADC) and the first and only treatment approved for this patient population.&nbsp;
ADCs are designed to target unique biomarkers such as the c-Met protein and deliver a potent &#8216;payload&#8217; directly to the biomarker-expressing cell.
Data from the Phase 2 LUMINOSITY study, designed to characterize the efficacy and safety of EMRELIS in c-Met overexpressing advanced NSCLC populations, support the FDA&#8217;s accelerated approval.
Findings from the study showed patients with high c-Met protein overexpression (n=84) who received Emrelis demonstrated a 35% Overall Response Rate (ORR) and Duration of Response (DOR) with a median of 7.2 months.
In&nbsp;December 2021, the FDA granted EMRELIS&nbsp;<a target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4408820-1&amp;h=2952437730&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4264002-1%26h%3D3470428670%26u%3Dhttps%253A%252F%252Fnews.abbvie.com%252F2022-01-04-AbbVie-Announces-U-S-FDA-Granted-Breakthrough-Therapy-Designation-BTD-to-Telisotuzumab-Vedotin-Teliso-V-for-Previously-Treated-Non-Small-Cell-Lung-Cancer%26a%3DBreakthrough%2BTherapy%2BDesignation%2Bby%2Bthe%2BFDA&amp;a=Breakthrough+Therapy+Designation" rel="noreferrer noopener">Breakthrough Therapy Designation</a> (BTD) based on Phase 2 LUMINOSITY study data.
Emrelis is being further evaluated as a monotherapy in patients with previously treated c-Met overexpressing NSCLC in the randomized Phase 3 confirmatory global study&nbsp;<a target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4408820-1&amp;h=741691694&amp;u=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04928846&amp;a=TeliMET+NSCLC-01" rel="noreferrer noopener">TeliMET NSCLC-01</a>.
Enrollment in the study is underway and continues across global clinical trial sites.
The FDA has also approved Roche Holdings AG&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) VENTANA&nbsp;MET (SP44) RxDx Assay, the only IHC companion diagnostic identifying patients eligible for Emrelis treatment.
On Wednesday, AbbVie&nbsp;and ADARx Pharmaceuticals announced a collaboration and license option agreement to develop small interfering RNA (siRNA) therapeutics across multiple disease areas, including neuroscience, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45405186/abbvie-and-adarx-pharmaceuticals-announce-collaboration-and-license-option-agreement-to-develop-ne" rel="noreferrer noopener">immunology, and oncology</a>.
siRNA represents a class of molecules capable of regulating gene expression and protein production. Unlike traditional modalities such as antibodies and small molecules, siRNA regulates gene expression. These molecules are designed to prevent the production of disease-causing proteins by targeting the messenger RNA (mRNA) that encodes for such proteins.
ADARx will receive a&nbsp;$335 million&nbsp;upfront payment and is eligible to receive several billion dollars in additional contingent payments, including option-related fees, milestone payments, and royalties.
Price Action: ABBV stock is down 5.32% at $177.96&nbsp;at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45416148/pony-ai-shares-rise-after-report-of-confidential-hong-kong-ipo-to-fund-robotaxi-expansion" target="_blank" rel="noreferrer noopener">Robotaxi Service Pony AI Stock Falls Despite IPO Buzz &#8211; Here&#8217;s Why</a></li>
</ul>
Photo via Shutterstock

ABBV

RHHBY

FDA Fast-Tracks AbbVie's New Lung Cancer Therapy Emrelis For Tough Lung Cancer Cases

Major cryptocurrencies are trading sideways amid stagnating Bitcoin dominance, potentially signaling increased capital rotation into altcoins.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$103,380.01</td>
<td>-0.9%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$2,600.38</td>
<td>-1.6%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$176.25</td>
<td>-1.5%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.55</td>
<td>-0.3%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.2335&nbsp;</td>
<td>-2.1%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001581</td>
<td>-2.7%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul class="wp-block-list">
<li>IntoTheBlock data shows large transaction volume increasing by 8.98% and daily active addresses grew by 10.7%. Transactions greater than $100,000 are down from 12,470 to 11,891 in a single day. Exchanges netflows are down by 236.9%.</li>
<li>Coinglass data reports 139,936 traders were liquidated in the past 24 hours for $408.44 million.</li>
<li>Crypto chart Ali Martinez <a href="https://x.com/ali_charts/status/1922625440864141717">observed</a> that over the past three weeks, 100,000 BTC have been withdrawn from exchanges, a sign of growing investor confidence and long-term holding behavior. During the same period, more than $35 billion <a href="https://x.com/ali_charts/status/1922548936356556816">flowed</a> through the crypto markets, underscoring heightened activity. &nbsp;</li>
<li>Martinez also <a href="https://x.com/ali_charts/status/1922364624533364831">highlighted</a> that if Bitcoin reclaims the $105,244 level, it could trigger $25.38 million in short liquidations, potentially fueling a sharp upside move as bearish positions get squeezed.</li>
</ul>
Notable Developments:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45416971/coinbase-becomes-first-pure-play-crypto-stock-in-sp-500-analyst-sees-major-institutional-upside">Coinbase Becomes First Pure-Play Crypto Stock In S&amp;P 500, Analyst Sees Major Institutional Upside</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45399602/standard-chartered-partners-with-falconx-to-fuel-institutional-crypto-access-as-bitcoin-soars-past-103k">Standard Chartered Partners With FalconX To Fuel Institutional Crypto Access As Bitcoin Soars Past $103K</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45399583/cryptocurrency-tycoons-daughter-escapes-kidnapping-attempt-viral-video-captures-terrifying-ordeal">Cryptocurrency Tycoon&#8217;s Daughter Escapes Kidnapping Attempt: Viral Video Captures Terrifying Ordeal</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45409339/jpmorgan-completes-first-public-trade-of-tokenized-treasuries">JPMorgan Completes First Public Trade Of Tokenized Treasuries</a></li>
<li><a href="https://www.benzinga.com/general/market-summary/25/05/45399288/kevin-oleary-lauds-robinhoods-acquisition-of-wonderfi-will-transform-cross-border-trading-no-more-outrageous-bank-fees">Kevin O&#8217;Leary Lauds Robinhood&#8217;s Acquisition Of WonderFi Will &#8216;Transform Cross-Border Trading:&#8217; &#8216;No More Outrageous Bank Fees&#8217;</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45397930/trump-memecoin-adopted-by-china-linked-nasdaq-company-as-treasury-reserve-asset">Trump Memecoin Adopted By China-Linked Nasdaq Company As Treasury Reserve Asset</a></li>
</ul>
Top Losers:
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Pi (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PI</a>)</td>
<td>&nbsp;$0.9652</td>
<td>-18.2%</td>
</tr>
<tr>
<td>EOS (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eos/usd">EOS</a>)</td>
<td>&nbsp;$0.8099</td>
<td>-8.7%</td>
</tr>
<tr>
<td>Floki (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">FLOKI</a>)</td>
<td>&nbsp;$0.0001089</td>
<td>-7.4%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Stockmoney Lizards noted that Bitcoin has strongly rebounded off key support, reinforcing the bullish structure. 
While the conservative target for this cycle is $150,000–$160,000, they see a more probable range between $200,000 and $250,000.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> bounced off this support like a rubber ball. 150 &#8211; 160k is the conservative target for this cycle. More likely 200 &#8211; 250k. Buy the dips&#8230; <a href="https://t.co/iaBoJ9I8Lt">pic.twitter.com/iaBoJ9I8Lt</a>
&mdash; Stockmoney Lizards (@StockmoneyL) <a href="https://twitter.com/StockmoneyL/status/1922705251921952951?ref_src=twsrc%5Etfw">May 14, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
CrediBULL Crypto <a href="https://x.com/CredibleCrypto/status/1922689184541573213">commented</a> that BTC bounced off local demand and is now consolidating, a structure that often precedes continuation moves. The key is whether Bitcoin can hold a higher low to resume its uptrend.
Michael van de Poppe pointed to a bearish divergence in Bitcoin dominance, suggesting the ongoing reversal may still have room to play out.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">A bearish divergence on <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> dominance implying that we&#39;re continuing the reversal. <a href="https://t.co/sqcuL8QACc">pic.twitter.com/sqcuL8QACc</a>
&mdash; Michaël van de Poppe (@CryptoMichNL) <a href="https://twitter.com/CryptoMichNL/status/1922697666154332287?ref_src=twsrc%5Etfw">May 14, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Crypto trader Javon Marks <a href="https://x.com/JavonTM1/status/1922646816148815889">observed</a> multiple bullish setups indicating Bitcoin could be on track to new all-time highs. Holding above $67,559 could trigger an 11% rally to $116,652, with a break above that targeting the $165,000 range.
Crypto analyst Miles Deutscher <a href="https://x.com/milesdeutscher/status/1922668266507600064">highlighted</a> that Bitcoin supply on exchanges has dropped to a 7-year low, now at just 14%. As demand rises and supply contracts, this sets up conditions for significant bullish pressure and potential price acceleration.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45416194/bitcoins-volatility-makes-it-unfit-as-a-benchmark-for-liquid-funds-report">Bitcoin&#8217;s Volatility Makes It Unfit As A Benchmark For Liquid Funds: Report</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$EOS

$ETH

$FLOKI

$SHIB

$SOL

$XRP

Bitcoin, Ethereum, XRP, Dogecoin Flat As Traders Hope For Altcoin Outperformance

The U.S. Food and Drug Administration (FDA) on Wednesday approved Merck &amp; Co. Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Welireg (belzutifan) for adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL).
This represents the first FDA approval of an oral therapy for PPGL,&nbsp;rare neuroendocrine tumors that can spread to other parts of the body.
Welireg received approval from <a target="_blank" href="https://www.merck.com/news/welireg-belzutifan-receives-first-european-commission-approval-for-two-indications/" rel="noreferrer noopener">the</a> FDA and European Medicines Agency for adult patients with advanced renal cell carcinoma&nbsp;(RCC).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44983460/mercks-q1-earnings-beat-wall-street-adjusts-2025-profit-outlook-as-tariffs-may-result-in-incremental-cost-of-200-million" rel="noreferrer noopener">Merck&#8217;s Q1 Earnings Beat Wall Street, Adjusts 2025 Profit Outlook As Tariffs May Result In Incremental Cost Of $200 Million</a>
Efficacy was evaluated in LITESPARK-015, an open-label, multi-cohort trial.
The major <a target="_blank" href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-pheochromocytoma-or-paraganglioma" rel="noreferrer noopener">efficacy</a> outcome measure was objective response rate (ORR). Additional efficacy outcome measures were duration of response (DOR) and the number of patients who had a reduction in at least one antihypertensive medication by at least 50%, maintained for at least six months.
<ul class="wp-block-list">
<li>ORR was 26%.</li>
<li>Median DOR was 20.4 months.</li>
<li>Of the 60 patients on baseline antihypertensive medications, 19 (32%) had a reduction in at least one antihypertensive medication by at least 50% for at least six months.</li>
</ul>
The recommended belzutifan dose for adults is 120 mg administered orally once daily.
The recommended dose for pediatric patients 12 years and older is based on body weight. For pediatric patients weighing ≥ 40 kg, the dose is 120 mg orally once daily.
For pediatric patients weighing &lt; 40 kg, the dose is 80 mg orally once daily.
In the first quarter of 2025, Welireg generated sales of $137 million, 62% year over year.
Price Action: MRK stock is down 3.45% at $73.98&nbsp;at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45411783/from-mine-to-magnet-mp-materials-and-maaden-plan-integrated-rare-earth-chain-in-saudi-arabia" target="_blank" rel="noreferrer noopener">From Mine To Magnet: MP Materials, Maaden Plan Rare Earth Chain In Saudi Arabia</a></li>
</ul>
Photo by tada images via Shutterstock

FDA Approves Merck's Kidney Cancer Drug For Rare Type Of Neuroendocrine Tumors

Newegg Commerce, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEGG#NASDAQ">NEGG</a>) shares are trading higher Wednesday. The company Tuesday announced the launch of AMD's EPYC 4005 Series server processors, available exclusively through Newegg <a href="https://www.benzinga.com//node/45374732">and Newegg Business</a>.
The Details: Newegg is offering the EPYC 4005 Series as a North American retail exclusive. The company described the new processors as &#8220;advanced, server-validated, and energy-efficient CPUs built for low-cost, easy-to-deploy systems tailored to growing businesses.&#8221;
&#8220;The AMD EPYC 4005 Series captures performance, price and practicality that small businesses require as they seek to acquire a system that meets their unique demands,&#8221; said Derek Dicker, corporate vice president, Enterprise and HPC Business, AMD. 
&#8220;Growing businesses will now have a compelling, right-sized solution, packaged in an affordable, easy-to-use platform that fits their current needs but can scale as their business grows.&#8221;
Related Link: <a href="https://www.benzinga.com/25/05/45414422/rocket-lab-stock-is-rallying-wednesday-whats-going-on">Rocket Lab Stock Is Rallying Wednesday: What&#8217;s Going On?</a>
NEGG Price Action: At the time of writing, Newegg shares are trading 48.4% higher at $7.71, according to data from <a href="https://www.bing.com/ck/a?!&amp;&amp;p=e2de60ae4675c406c3d8cc7556e2420ba39e0a53615bec22b41e24ab0b054f71JmltdHM9MTc0NzE4MDgwMA&amp;ptn=3&amp;ver=2&amp;hsh=4&amp;fclid=2811d019-9dca-691d-17e3-c5fc9cdc684f&amp;psq=benzinga+pro&amp;u=a1aHR0cHM6Ly93d3cuYmVuemluZ2EuY29tL3Byby9sb2dpbg&amp;ntb=1">Benzinga Pro.</a>
Image: This illustration was generated using artificial intelligence via Midjourney.

NEGG

What's Going On With Newegg Shares Wednesday?

Silicon Laboratories, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLAB#NASDAQ">SLAB</a>) shares are<a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener"> trading relatively flat on Wednesday.</a>
On Tuesday, the company reported first-quarter results, with revenues of $178 million, beating the Street View. Industrial &amp; Commercial revenue for the quarter was $96 million, up 47% year-over-year, while Home &amp; Life revenue for the quarter was $82 million, up 99%.
Here are the key analysts&#8217;<a target="_blank" href="https://www.benzinga.com/quote/SLAB/analyst-ratings" rel="noreferrer noopener"> takeaways from the earnings:</a>
<ul class="wp-block-list">
<li>Benchmark analyst Cody Acree reiterated the Buy rating on the stock, with a price forecast of $160.</li>
<li>Needham analyst N. Quinn Bolton reiterated the Buy rating on Silicon Laboratories, with a price forecast of $150.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45406180/only-half-of-sp-500-stocks-joined-the-tariff-relief-rally-time-to-buy-the-laggards" rel="noreferrer noopener">Only Half Of S&amp;P 500 Stocks Joined The Tariff-Relief Rally: Time To Buy The Laggards?</a>
Benchmark: Acree notes that Silicon Labs (SLAB) experienced a quarter-over-quarter improvement in customer bookings and distribution point-of-sale trends during the first quarter, with this positive momentum continuing into the second quarter.
This suggests that both customer and channel inventory levels have returned to more typical levels. The company&#8217;s end markets are also gradually recovering from their cyclical downturn.
Silicon Labs reaffirmed its confidence in the full-year outlook shared at its March 11 analyst day. The company remains on track to meet the FY25 Street revenue estimate of $785 million.
Acree anticipates modest upward revisions to consensus following the latest positive results and guidance. T
To reach his updated FY25 forecast of $789.2 million, Acree projects the firm to deliver mid-single-digit quarter-over-quarter growth in the third and fourth quarters, translating to $203 million and $216 million in sales, respectively—figures that closely align with current market expectations.
Needham: Bolton notes that management has reaffirmed its expectation of more than 20% year-over-year revenue growth for FY25, while he projects a higher 33% increase, citing minimal impact from tariffs.
Gross margins are performing better than anticipated, driven by a favorable product mix and stable pricing. As a result, the company revised margin forecasts slightly upward.
Bolton projects second-half growth to be supported by the ramp-up of design wins in areas such as smart metering, continuous glucose monitors (CGMs), and electronic shelf labels (ESLs).
The analyst also observes that inventory levels are being well managed, with only moderate sequential increases expected through the first quarter of FY26.
Price Action: Silicon Laboratories shares are trading lower by 0.93% to $132.46 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/05/45399438/smci-rated-outperform-by-raymond-james-amid-dominance-in-branded-ai-server-market" target="_blank" rel="noreferrer noopener">SMCI Stock In ‘Sweet Spot,' Says Raymond James — Sets $41 Price Target As AI Revenue Hits 70%</a></li>
</ul>
Image: Shutterstock

Equities

Markets

SLAB

Silicon Labs Revenue Beats Estimates, Analysts Highlight Inventory Recovery

Making weight loss injections available to all eligible individuals in the U.K. could yield an economic boost of 4.5 billion pounds (around $5.99 billion) annually, according to new research presented at the European Congress <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">on Obesity in Málaga, Spain</a>.
The findings highlight the broader societal and productivity benefits of Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) semaglutide, a drug known by brand names such as Wegovy and Ozempic.
Globally, obesity is projected to affect 3.8 billion adults and nearly 750 million children and adolescents by 2050.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45341500/eli-lillys-zepbound-shows-superior-weight-loss-over-novo-nordisks-wegovy-in-head-to-head-trial" rel="noreferrer noopener">Eli Lilly&#8217;s Zepbound Shows Superior Weight Loss Over Novo Nordisk&#8217;s Wegovy In Head-To-Head Trial</a>
In the U.K., 26.5% of adults are currently obese, and 4.6 million people live with type 2 diabetes. These conditions cost the U.K. an estimated 100 billion pounds annually in healthcare and related expenses, according to the Guardian report.
The study examined data from 2,660 participants in U.K. clinical trials who were living with obesity and/or type 2 diabetes.
Researchers found that those taking semaglutide could work five additional days per year and contribute 12 extra days of unpaid labor, such as volunteering or childcare.
This increase in productivity translated to an average annual &#8220;net production value&#8221; of 1,127 pounds per person.
Applied nationally, the researchers estimated potential productivity gains of 4.31 billion pounds from treating individuals with severe obesity and 200 million pounds from treating those with type 2 diabetes.
Currently, NHS guidelines recommend semaglutide for patients with a BMI of 35 or higher and at least one weight-related condition.
However, some experts cautioned against widespread access due to high drug costs.
The U.K. Health Secretary Wes Streeting acknowledged the findings, calling the drugs &#8220;colossal&#8221; tools in the fight against obesity and a potential means to reintegrate unemployed Britons into the workforce. He said the government would carefully assess the research.
Semaglutide and liraglutide may also have implications beyond weight loss.
Citing another study presented at the Málaga conference, the Guardian <a target="_blank" href="https://www.theguardian.com/society/2025/may/09/weight-loss-jabs-bolster-uk-economy-study-semaglutide" rel="noreferrer noopener">report</a> on Friday highlighted that overweight adults taking the drugs cut their alcohol consumption by nearly two-thirds in just four months.
The study tracked 262 individuals in Ireland and Saudi Arabia and reported a drop in weekly alcohol intake from 11.3 to 4.3 units. Among regular drinkers, consumption fell from 23.2 to 7.8 units—an effect greater than that seen with nalmefene, a drug currently prescribed in Europe for alcohol use disorder.
Price Action: NVO stock is down 1.67% at $64.31 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/05/45411513/kraft-heinz-bets-3-billion-on-us-factory-overhaul-to-offset-tariff-impact-report" target="_blank" rel="noreferrer noopener">Kraft Heinz Bets $3 Billion On US Factory Overhaul To Offset Tariff Impact: Report</a></li>
</ul>
Photo by KK Stock via Shutterstock

Eurozone

Novo Nordisk's Ozempic Weight Loss Jabs Could Boost UK Economy By $6 Billion, Study Finds

Reddit Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NASDAQ">RDDT</a>) shares are surging 10.2% to $124.32 Wednesday afternoon, extending a rally that has seen the stock climb 25% over the past month.
The recent, sharp rise follows the company's stronger-than-expected <a href="https://www.benzinga.com/general/social-media/25/05/45178546/reddit-executives-see-strong-growth-in-q2-and-beyond">first-quarter earnings</a>, released after the market closed on May 1, which showcased accelerating revenue, improved profitability and robust user growth.
What To Know: Reddit posted <a href="https://www.benzinga.com/quote/RDDT/earnings">earnings</a> of 13 cents per share, beating consensus estimates of 2 cents. Revenue came in at $392.36 million, topping expectations of $370.01 million and marking a 61% year-over-year gain in advertising revenue. 
The company also reported <a href="https://www.benzinga.com/general/social-media/25/05/45209108/reddit-rallies-on-ad-surge-global-growth-analyst-upgrades-to-buy">108.1 million</a> daily active users, up 31% from the previous year, and a net income of $26.2 million, a sharp reversal from a $575.1 million loss in the prior-year period.
Read Also: <a href="https://www.benzinga.com/news/25/05/45412383/hims-hers-stock-pulls-back-after-strong-q1-earnings-115-gain-over-past-month">Hims &amp; Hers Stock Pulls Back After Strong Q1 Earnings, 115% Gain Over Past Month</a>
CEO Steve Huffman <a href="https://www.benzinga.com/general/social-media/25/05/45151798/reddit-stock-soars-after-better-than-expected-q1-daily-active-uniques-up-31-ad-revenue-up-61-and-more">highlighted</a> the platform's growing appeal, citing weekly active users exceeding 400 million. CFO Drew Vollero noted strong momentum in ad pricing and international expansion, with Reddit guiding second-quarter revenue between $410 million and $430 million.
Analysts <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45176569/reddits-ad-strategy-is-clicking-say-analystsstrong-q1-sets-stage-for-profitable-growth-in-2025">responded</a> positively. Seaport Global upgraded Reddit to Buy, while Needham and JP Morgan raised price targets to $145. The consensus signals growing confidence in Reddit's monetization strategy, international push and long-term growth potential despite macro and search-related headwinds.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45415824/whats-going-on-with-airbnb-stock-today">What&#8217;s Going On With Airbnb Stock Today?</a>
<h2 class="wp-block-heading">How To Buy RDDT Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Reddit&#8217;s case, it is in the Communication Services sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, RDDT has a 52-week high of $230.41 and a 52-week low of $49.13.

RDDT

Reddit (RDDT) Stock Is Up 25% Over The Past Month: What's Going On?

Carvana Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) shares are trading higher by 6.6% to $311.64 Wednesday afternoon, extending a sharp rally that has lifted the stock 52% over the past month.
The surge follows a strong <a href="https://www.benzinga.com/news/earnings/25/05/45268560/carvana-q1-earnings-revenue-eps-beat-estimates-as-vehicles-sales-jump-46-company-remains-on-track-for-significant-growth-in-fy25">first-quarter earnings</a> report released last week, in which the online used car retailer posted record-setting results and raised its full-year outlook.
What To Know: For the first-quarter, Carvana reported revenue of $4.23 billion and adjusted EBITDA of $488 million, both ahead of Wall Street estimates. Retail unit sales soared 46% year-over-year to a <a href="https://www.benzinga.com/pressreleases/25/05/b45265795/carvana-announces-record-first-quarter-2025-results">record</a> 133,898 vehicles, surpassing expectations and driving profitability to new highs.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45417105/tesla-stock-continues-to-climb-whats-going-on">Tesla Stock Continues To Climb: What&#8217;s Going On?</a>
Analysts <a href="https://www.benzinga.com/25/05/45285512/carvana-analysts-boost-their-forecasts-after-upbeat-q1-results">responded</a> favorably. BofA Securities reiterated a Buy rating and lifted its price target to $295, citing strong operational efficiency and expanding financing margins. Wells Fargo and Baird also raised their targets to $310 and $275, respectively, while Needham maintained a $340 target.
Looking ahead, Carvana projects further sequential gains in the second-quarter, expecting 138,000 units sold and $536 million in adjusted EBITDA. Management also reaffirmed its long-term goal of selling 3 million units annually at a 13.5% EBITDA margin.
Read Also: <a href="https://www.benzinga.com/news/earnings/25/05/45417576/nu-holdings-stock-bounces-back-from-q1-earnings-sell-off-whats-going-on">Nu Holdings Stock Bounces Back From Q1 Earnings Sell-Off: What&#8217;s Going On?</a>
<h2 class="wp-block-heading">How To Buy CVNA Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Carvana&#8217;s case, it is in the Consumer Discretionary sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, CVNA has a 52-week high of $311.88 and a 52-week low of $97.55.
Image courtesy of Carvana

CVNA

Carvana (CVNA) Stock Is Up 52% Over The Past Month: What's Going On?

Rigetti Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) shares are trading higher Wednesday. The company reported first-quarter earnings on Monday after <a href="https://www.benzinga.com//node/45379735">the market closed.</a>
What To Know: The company reported earnings per share of 13 cents, beating the consensus estimate of a 6 cent-loss. In addition, it reported sales of $1.47 million, missing the consensus estimate of $2.55 million and representing a 51.77% decrease in sales year-over-year.
Rigetti reported that as of April 30 it had $237.7 million in cash, cash equivalents and available-for-sale investments.
During the quarter, the company was selected to participate in the Defense Advanced Research Projects Agency&#8217;s Quantum Benchmarking Initiative. It was also granted an Air Force Office of Scientific Research award to further develop certain chip fabrication technology.
&#8220;We also are making great strides in developing innovative approaches to scaling to higher qubit count systems, which is possible due to our open and modular system architecture, in-house full-stack expertise, and world-class partners.&#8221;
Following the earnings report, Needham analyst Quinn Bolton maintained a Buy rating on Rigetti and lowered the price target from&nbsp;$17&nbsp;to&nbsp;$15.
Related Link: <a href="https://www.benzinga.com/25/05/45414422/rocket-lab-stock-is-rallying-wednesday-whats-going-on">Rocket Lab Stock Is Rallying Wednesday: What&#8217;s Going On?</a>
RGTI Price Action: At the time of writing, Rigetti stock is trading 19.4% higher at $11.78, according to data from <a href="https://www.benzinga.com/pro/login">Benzinga Pro.</a>
Image: via Shutterstock

RGTI

Rigetti Stock Is Soaring Wednesday: What's Going On?

First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) is in the midst of a likely short squeeze, which is skyrocketing the stock. Once the squeeze is over, shares should fall back to relative congestion support.
So today, let&#8217;s place a trade on First Solar against the current trade, but give the chart some time to develop by setting the expiration at least 60 days to deliver results.
Here&#8217;s how best to do it.
First Solar&#8217;s resistance zone currently sits around $200, but with all this market uncertainty, trading could be choppy in the summer months. Support sits near $155, which is where we&#8217;ll put our middle strike.
The way to play this is with a long put butterfly, a combination of a long put spread, and a short put spread that share the same short strike and same expiration date. Though this kind of trade is often described as &#8220;delta neutral,&#8221; it certainly delivers profit if price action fades as expected. 
<ul class="wp-block-list">
<li>Buy to open 1 FSLR 15 Aug 175 puts </li>
<li>Sell to open 2 FSLR 15 Aug 155 puts </li>
<li>Buy to open 1 FSLR 15 Aug 135 puts </li>
</ul>
Set an alert for prices near the middle strike so that you are very aware of the motion into the middle strike, as this is where the maximum profit will engage into expiration. You will also notice that price action is less sensitive to fluctuation the further we are from expiration. 
This long-put butterfly currently has a debit of $1.55, which represents the total risk incurred in the trade. The breakeven price of the stock at expiration on this trade is $173.45, less commissions.
The highest potential profit is $20 (the distance between $175 and $155), less the cost of the debt incurred by buying the call butterfly, so $20 &#8211; $1.55 = $18.45 less commissions.
It is extremely rare to collect all this premium in this kind of butterfly. Consider price action information to drive your risk and profit parameters.
This strategy provides several ways to exit, but I will discuss the main two:
<ol class="wp-block-list">
<li>Sell the put butterfly when the profit goal moves into your target parameters, particularly once the middle strike is tested near the expiration time. I often look for an 80% to 200% return for these types of put butterflies, but the maximum profit potential is much greater.</li>
<li>To sell the put butterfly when your loss threshold is breached. Customarily, this is 50% for me. </li>
</ol>
More advanced traders might consider rolling the short strikes down over time if First Solar&#8217;s price continues to fall.
<h2 class="wp-block-heading">Meet Your One-Stop Command Center for Smarter Investing</h2>
Newsletters talk. Analysts argue. Talking heads on TV hype. Benzinga Edge does something different—it delivers. With real-time portfolio alerts, actionable stock ideas, and pro-grade tools…you get the complete investors&#8217; arsenal — ready to help you profit in any market. Get Your Edge Now right <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-3/">HERE</a> (At 43% New-Member Discount)
Editorial content from our Expert contributors is intended to be information for the general public and not individualized investment advice. Editors/contributors are presenting their individual opinions and strategies, which are neither expressly nor impliedly approved or endorsed by Benzinga.
Photo: Shutterstock

Opinion

FSLR

This Week's Best Short Squeeze Options Trade

Rigetti Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>)&nbsp;shares are surging on Wednesday, reversing from yesterday&#8217;s decline.
This week, the company reported&nbsp;first-quarter&nbsp;revenue of&nbsp;$1.47 million, missing analyst estimates of&nbsp;$2.55 million and&nbsp;earnings of 13 cents per share, beating estimates <a target="_blank" href="https://www.benzinga.com//node/45379735" rel="noreferrer noopener">for a loss of 6 cents per share</a>.
Needham analyst N. Quinn Bolton lowered the price forecast from $17.00 to $15.00, while keeping a <a href="https://www.benzinga.com/quote/RGTI/analyst-ratings">Buy rating</a>.
The analyst writes that revenue fell short of their expectations, pending reauthorization of the DOE Quantum Leadership Act (formerly the NQI).
Bolton highlighted key takeaways, including DARPA&#8217;s selection for its QBI program (Stage A) and the $5.48 million AFOSR award for the development of Alternating-Bias-Aided Annealing (ABAA) fabrication technology.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/04/44928729/rigetti-scores-4-6-million-uk-grant-to-tackle-quantum-error-correction" rel="noreferrer noopener">Rigetti Scores $4.6 Million UK Grant To Tackle Quantum Error Correction</a>
Bolton stated that the company achieved the optical control of superconducting qubits, which could reduce thermal load and physical footprint in future systems.
Also, the analyst stated that the company&#8217;s efforts to increase its U.K. presence with three Innovate U.K. Quantum Mission Pilot Awards and demonstration of optical control of a superconducting qubit, along with completion of Quanta Computer&#8217;s $35 million investment.
In the bear case, the analyst points to cash burn risk, which could lead to more capital raises and shareholder dilution.
Bolton slashed revenue estimates to $6.8 million (from $13.5 million) for 2025 and $15.0 million (from $25.0 million) for 2026.
Price Action: RGTI shares are up 19.70% at $11.80&nbsp;at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/new-etfs/25/04/44866215/exclusive-defiance-letting-you-go-2x-long-on-quantum-2x-short-on-ai-straight-from-the-ceo" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Why Defiance Is Letting You Go 2X Long On Quantum, And 2X Short On AI, Straight From The CEO</a></li>
</ul>
Photo Courtesy Bartlomiej K. Wroblewski via Shutterstock

Price Target

Tech

Why Did Rigetti Computing Analyst Cut His Price Forecast?

TSEM

Tower Semiconductor shares are trading higher after the company reported Q1 financial results and beat its adjusted EPS and revenue estimates.

ENPH

Enphase Energy shares are trading higher after the company announced New York homeowners in certain territories can now quality to enroll in the NYSERDA battery incentive program.

he partnership will bring greater convenience to users of two of Brazil's most-loved apps, powering a new ride-hailing tab in iFood and a delivery tab in Uber
Uber Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) and iFood, one of the world's leading food delivery players, announced today a strategic partnership to offer more convenience for millions of consumers in Brazil. The partnership will allow iFood users to book Uber rides directly from the iFood app, while Uber users will gain access to iFood's food, grocery, pharmacy, and convenience delivery services within the Uber app.

UBER

Uber Technologies And iFood Partner To Enhance Mobility And Delivery In Brazil

Invivyd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-05-15. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Invivyd will report an earnings per share (EPS) of $-0.01.
Invivyd bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings Track Record</h3>
During the last quarter, the company reported an EPS beat by $0.18, leading to a 0.08% drop in the share price on the subsequent day.
Here's a look at Invivyd's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.33</td>
<td>-0.35</td>
<td>-0.36</td>
<td>-0.38</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.15</td>
<td>-0.51</td>
<td>-0.40</td>
<td>-0.38</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-0.0%</td>
<td>-4.0%</td>
<td>6.0%</td>
<td>-7.000000000000001%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747249626_0.png" alt="eps graph" />
<h3>Tracking Invivyd's Stock Performance</h3>
Shares of Invivyd were trading at $0.8609 as of May 13. Over the last 52-week period, shares are down 67.79%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/IVVD/earnings">To track all earnings releases for Invivyd visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

IVVD

What to Expect from Invivyd's Earnings

Katapult Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPLT#NASDAQ">KPLT</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-05-15. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Katapult Holdings will report an earnings per share (EPS) of $-0.72.
Katapult Holdings bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS missed by $0.68, leading to a 0.0% drop in the share price on the subsequent day.
Here's a look at Katapult Holdings's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.09</td>
<td></td>
<td>-1.21</td>
<td>-1.32</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.77</td>
<td>-0.94</td>
<td>-1.27</td>
<td>0.23</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-8.0%</td>
<td>-5.0%</td>
<td>-1.0%</td>
<td>-8.0%</td>
</tr>
</tbody>
</table>

<h3>Market Performance of Katapult Holdings's Stock</h3>
Shares of Katapult Holdings were trading at $6.97 as of May 13. Over the last 52-week period, shares are down 61.67%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/KPLT/earnings">To track all earnings releases for Katapult Holdings visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

KPLT

Katapult Holdings Earnings Preview

ACHC

Acadia Healthcare shares are trading lower after several firms cut their respective price targets on the stock.

Press Releases

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study

Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference

Comments

Vir Biotechnology

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL